US drug pricing legislation drives biotech business to adapt for further innovation

Financial markets remained volatile throughout the third quarter, and the healthcare sector was no exception. The US Inflation Reduction Act (IRA) signed into law in mid-August had an impact on biotech stocks. The IRA establishes a new framework for federal spending on prescription drugs but is not expected to jeopardize US leadership in medical innovation.